# South Korea Fertility Drug Surgery Market

> South Korea Fertility Drug Surgery Market Research Report By Underlying Cause (Male, Female), By Drugs (Clomiphene Citrate, Letrozole), By Procedures (Hysteroscopy, Laparoscopy, Robotic Laparoscopy) and By End User (Fertility Clinics) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.79%
- **2024:** $ 50.5 Million
- **2025:** $ 53.93 Million
- **2035:** $ 104 Million
- **Key Players:** Merck KGaA (DE), Ferring Pharmaceuticals (CH), Bayer AG (DE), AbbVie Inc. (US), Eli Lilly and Company (US), SAGE Therapeutics (US), HRA Pharma (FR), Irvine Scientific (US)

**Report ID:** MRFR/Pharma/52247-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-fertility-drug-surgery-market-54009

---

## Market Summary

## **South Korea Fertility Drug Surgery Market Overview**

As per MRFR analysis, the South Korea Fertility Drug Surgery Market Size was estimated at 40.6 (USD Million) in 2023. The South Korea Fertility Drug Surgery Market Industry is expected to grow from 44(USD Million) in 2024 to 93 (USD Million) by 2035. The South Korea Fertility Drug Surgery Market CAGR (growth rate) is expected to be around 7.041% during the forecast period (2025 - 2035).

**Key South Korea Fertility Drug Surgery Market Trends Highlighted**

South Korea's fertility drug surgery market is currently undergoing significant changes, influenced by various factors. One key market driver is the increasing awareness and acceptance of assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and related procedures. The government has been promoting these technologies to combat declining birth rates. As reported by the South Korean government, the birth rate has reached lower levels, prompting initiatives that encourage family growth. This governmental focus directly supports the growth of the fertility drug and surgery market.

Opportunities in the South Korean market include expanding access to fertility treatments for a wider demographic.With the rise in infertility rates among young couples, more individuals are seeking help, leading to a demand for innovative treatments and services. Clinics are exploring new technologies, such as genetic testing and personalized medicine, creating a path for enhanced patient outcomes. The trend toward combining traditional fertility drugs with advanced surgical techniques is also emerging, as healthcare providers strive for higher success rates with fewer interventions. In recent times, South Korean society hasshown a shift in perception regarding fertility treatments.

Younger generations are becoming less stigmatized about seeking help for fertility issues, resulting in a higher number of individuals willing to explore available options.This cultural shift is driving increased demand for fertility drug surgery, enabling clinics to expand their portfolios in response to consumer preferences. Overall, the South Korea fertility drug surgery market is adapting to demographic changes, technological advancements, and societal trends, fostering an environment ripe for growth and innovation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Fertility Drug Surgery Market Drivers**

**Increasing Infertility Rates**

The primary driver of the South Korea fertility drug surgery market is the growing prevalence of infertility among couples. The number of infertile couples has significantly increased, according to South Korea's National Statistical Office, with 15% of couples expected to face reproductive difficulties in 2020. This figure shows that the demand for fertility treatments and associated surgical procedures is rising, which is driving the fertility drug surgery market in South Korea. Furthermore, groups like the Korean Society of Obstetrics and Gynecology are aggressively raising awareness of fertility-related concerns, which helps to address infertility and expand the market.

The South Korea fertility drug surgery market is anticipated to continue expanding due to the rise in therapies available as more people seek assistance.

**Advancements in Medical Technology**

Technological advancements in reproductive medicine are significantly influencing the growth of the South Korea Fertility Drug Surgery Market Industry. Innovations such as minimally invasive surgical techniques and novel fertility drugs enhance both efficacy and safety in fertility treatments, appealing to a larger segment of the population. 
The Ministry of Health and Welfare in South Korea emphasizes the integration of advanced technologies in healthcare practices, which has led to the introduction of improved methods in fertility treatments.Furthermore, patents filed for new fertility technologies, such as preimplantation genetic testing, indicate a robust Research and Development environment, thereby stimulating market expansion.

**Government Support and Regulation**

The South Korean government has been actively supporting fertility treatments through various policies and financial incentives, contributing to the growth of the South Korea Fertility Drug Surgery Market Industry. The Korean Ministry of Health and Welfare launched initiatives aimed at subsidizing fertility treatment costs for couples, making it more accessible to a broader population.

As per recent government filings, a budget allocation for fertility treatments increased by 30% in the past five years.This support not only encourages couples to seek medical help for infertility but also stimulates the market by enabling clinics and hospitals to expand their services and offerings in the South Korea Fertility Drug Surgery Market.

**South Korea Fertility Drug Surgery Market Segment Insights**

**Fertility Drug Surgery Market Underlying Cause Insights**

The Underlying Cause segment of the South Korea Fertility Drug Surgery Market plays a critical role in identifying and addressing the factors contributing to infertility among couples. Infertility remains a pressing health concern in South Korea, where societal trends, such as delayed marriage and childbearing, have led to increased awareness regarding reproductive health issues. The segment is divided into two primary categories: Male and Female infertility factors. Male infertility often stems from conditions related to sperm production, motility issues, or hormonal imbalances, which have been observed to increasingly impact the ability to conceive.

As awareness grows, more men are seeking medical intervention for fertility issues, leading to a significant focus on targeted treatments and advancements in male reproductive health services. On the other hand, Female infertility frequently results from conditions such as polycystic ovary syndrome (PCOS), endometriosis, and age-related factors that affect ovulation. Female infertility has gained attention as healthcare providers in South Korea work to implement comprehensive treatment options that consider both medicinal and surgical approaches. The country's healthcare system is evolving to better cater to the unique needs of women experiencing fertility challenges.

Lifestyle changes, societal pressures, and a growing willingness to seek professional help to address these issues contribute to the strong presence of the Female category within the Underlying Cause segment. As families become more focused on balancing work and life, the demand for effective fertility solutions has seen a steady rise. The South Korea Fertility Drug Surgery Market segmentation offers insights into how various underlying causes affect reproductive health, emphasizing the importance of understanding the demographics and health conditions of both men and women.

Moreover, with the increased collaboration between healthcare providers and fertility specialists, patients can access personalized care that addresses the specific causes of infertility. The growing emphasis on research in this sector continues to unlock opportunities for innovative treatments and interventions, fostering an environment enriched with potential breakthroughs in the field of reproductive health. Understanding the dynamics of the Underlying Cause segment is essential in shaping policy, healthcare strategies, and support systems to combat infertility effectively in South Korea, where evolving social norms and family planning practices have become central issues for many couples navigating the complexities of conceiving.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Fertility Drug Surgery Market Drugs Insights**

The Drugs segment within the South Korea Fertility Drug Surgery Market presents a significant area of focus as it contributes substantially to the overall reproductive health landscape in the country. Clomiphene Citrate has emerged as a pivotal choice among healthcare professionals and patients alike, playing a vital role in treating infertility by stimulating ovulation in women. Its relevance is underscored by the growing incidence of reproductive disorders in South Korea, where lifestyle changes and delayed pregnancies are prominent.

Letrozole is gaining importance as an alternative, particularly for women with polycystic ovary syndrome (PCOS), providing effective ovulation induction.The increasing awareness around fertility treatments, coupled with advancements in reproductive endocrinology, has led to a surge in demand for these medications. Moreover, the South Korean government supports fertility treatments through various initiatives, fostering a conducive environment for the Drugs segment to thrive. With high accessibility and the focus on improving fertility rates in the nation, both Clomiphene Citrate and Letrozole are poised to significantly influence the trajectory of the Fertility Drug Surgery Market in South Korea.

**Fertility Drug Surgery Market Procedures Insights**

The South Korea Fertility Drug Surgery Market is witnessing a notable focus on the Procedures segment, which includes techniques such as Hysteroscopy, Laparoscopy, and Robotic Laparoscopy. Hysteroscopy plays a crucial role in diagnosing and treating intrauterine conditions, which can significantly enhance reproductive outcomes. This method is increasingly preferred due to its minimally invasive nature, leading to shorter recovery times and reduced healthcare costs.

Laparoscopy is another key player, known for its efficacy in addressing various fertility-related issues, such as endometriosis and ovarian cysts, providing surgeons with a clear view of the pelvic organs while minimizing tissue damage.The emergence of Robotic Laparoscopy is revolutionizing the Procedures domain, offering enhanced precision and control, which is highly valued in delicate surgical operations. The increasing prevalence of infertility concerns in South Korea is driving the demand for advanced surgical procedures, contributing to a robust growth trajectory in the market.

With favorable government policies and technological advancements, the market is well-positioned to advance in these procedural methodologies, further boosting the overall effectiveness of fertility treatments.

**Fertility Drug Surgery Market End User Insights**

The End User segment of the South Korea Fertility Drug Surgery Market predominantly includes Fertility Clinics, which play a critical role in the healthcare system, addressing infertility issues. In recent years, there has been an increasing demand for advanced reproductive technologies, contributing to the growth of these clinics. With a significant rise in cases of infertility, owing to factors such as delayed parenthood and lifestyle changes, Fertility Clinics are vital as they provide specialized treatments and personalized care to patients.

These clinics are equipped with state-of-the-art technology and employ expert staff to administer fertility drug surgeries, enhancing the chances of successful conception.The South Korean government has been supportive of reproductive health initiatives, leading to more couples opting for fertility treatments. As the increasing acceptance of assisted reproductive technologies continues to shape patient attitudes, Fertility Clinics are witnessing substantial growth, making them a dominant force within the South Korea Fertility Drug Surgery Market.

The high success rates and advancements in procedures at these clinics further reinforce their importance, ensuring that they remain pivotal in addressing the growing needs of individuals experiencing fertility challenges.

**South Korea Fertility Drug Surgery Market Key Players and Competitive Insights**

The South Korea Fertility Drug Surgery Market is characterized by its evolving competitive landscape, driven by increasing awareness of reproductive health and advancements in medical technology. With a growing number of players entering the market, the competitive dynamics are influenced by factors such as product innovation, regulatory frameworks, and shifting consumer preferences. Companies engage in strategic partnerships, mergers, and acquisitions to enhance their market positioning and expand their product offerings. Additionally, the rising demand for fertility treatments and the increasing prevalence of infertility issues contribute to the growth opportunities in this sector.

Market players are also focusing on expanding their clinical research capabilities to develop more effective treatments and address the unique needs of patients in South Korea.ISU Abxis has established a notable presence in the South Korea Fertility Drug Surgery Market, driven by its strong commitment to developing innovative therapies that address the challenges of fertility. The company leverages advanced biotechnology to create products that improve reproductive health outcomes. ISU Abxis benefits from a well-established distribution network within the region, allowing for efficient product delivery to healthcare providers.

The company's emphasis on rigorous research and development has resulted in a portfolio that includes various fertility-related drug formulations. Its ability to collaborate with hospitals and fertility clinics enhances its competitive edge and solidifies its reputation as a trusted name in reproductive health solutions within South Korea.Korea Otsuka Pharmaceutical plays a pivotal role in the South Korea Fertility Drug Surgery Market, offering a range of key products and services tailored to meet the needs of patients and healthcare professionals. The company's focus on research and development allows it to introduce effective fertility treatments that are well-received in the market.

With an extensive understanding of local healthcare dynamics, Korea Otsuka Pharmaceutical has built strong relationships with healthcare institutions, facilitating wide product accessibility. The company's strengths lie in its innovative approach to fertility solutions, as well as its commitment to improving patient outcomes. Strategic partnerships and collaborations further enhance its market presence, enabling the company to remain competitive amid a rapidly evolving industry landscape.

**Key Companies in the South Korea Fertility Drug Surgery Market Include**

- ISU Abxis
- Korea Otsuka Pharmaceutical
- Samsung Biologics
- Shin Poong Pharmaceutical
- AhnGook Pharmaceutical
- Celltrion
- OCI Company
- Sihuan Pharmaceutical
- Genexine
- LG Chem
- Boryung Pharmaceutical
- Hanmi Pharmaceutical
- Daewoong Pharmaceutical
- Korea Pharmaceutical
- Korea Drug

**South Korea Fertility Drug Surgery Market Industry Developments**

In recent months, the South Korea Fertility Drug Surgery Market has witnessed significant developments. Notable advancements in technology, coupled with increasing public awareness surrounding fertility issues, have intensified the demand for fertility treatments. Companies like Celltrion and Samsung Biologics have reported enhanced capacities to produce biologic drugs targeting fertility enhancement, reflecting a growing focus in this sector. Furthermore, the market is experiencing growth with the government facilitating access to fertility treatments, exemplified by policies aimed at subsidizing costs for assisted reproductive technologies.

In terms of mergers and acquisitions, in March 2023, Hanmi Pharmaceutical announced its acquisition of a local biotech firm specializing in fertility solutions, enhancing its portfolio in this growing market. Additionally, Genexine's partnerships with international firms translated to expanded R&D investments localized in South Korea, fostering innovation in fertility drugs. The South Korean Fertility Drug Surgery Market was valued significantly higher in 2022 compared to the previous year, driven by factors such as rising infertility rates and increasing societal acceptance of fertility treatments.

Given these dynamics, the market appears poised for healthy growth moving forward, particularly with ongoing advancements in drug formulations and surgical techniques aimed at improving patient outcomes.

**South Korea Fertility Drug Surgery Market Segmentation Insights**

**Fertility Drug Surgery Market Underlying Cause****Outlook**

- Male
- Female

**Fertility Drug Surgery Market Drugs****Outlook**

- Clomiphene Citrate
- Letrozole

**Fertility Drug Surgery Market Procedures****Outlook**

- Hysteroscopy
- Laparoscopy
- Robotic Laparoscopy

**Fertility Drug Surgery Market End User****Outlook**

- Fertility Clinics

## Market Drivers

### Rising Incidence of Infertility

The rising incidence of infertility in South Korea serves as a significant driver for the fertility drug-surgery market. Factors such as delayed childbearing, lifestyle changes, and environmental influences contribute to this trend. Recent statistics indicate that around 1 in 6 couples in South Korea face infertility challenges, which has led to a growing need for effective treatment solutions. As the population grapples with these issues, the demand for fertility drugs and surgical procedures is expected to increase. This trend suggests that the fertility drug-surgery market will continue to expand, as healthcare providers respond to the needs of couples seeking assistance in their journey to parenthood.

### Supportive Regulatory Environment

A supportive regulatory environment plays a pivotal role in shaping the fertility drug-surgery market. In South Korea, government policies and regulations have been established to promote fertility treatments and ensure patient safety. Initiatives such as subsidies for fertility treatments and the establishment of guidelines for clinics contribute to a more accessible healthcare landscape. This regulatory support encourages investment in the fertility drug-surgery market, as healthcare providers are more likely to expand their services and adopt new technologies. Consequently, the fertility drug-surgery market is poised for growth, driven by a favorable regulatory framework that prioritizes reproductive health.

### Cultural Shifts Towards Family Planning

Cultural shifts towards family planning are influencing the fertility drug-surgery market in South Korea. As societal norms evolve, there is a growing acceptance of assisted reproductive technologies among younger generations. This shift is reflected in the increasing number of couples opting for fertility treatments, as they seek to balance career aspirations with family planning. The fertility drug-surgery market is likely to benefit from this trend, as more individuals view fertility treatments as viable options rather than stigmatized choices. This cultural transformation may lead to a sustained increase in demand for fertility drugs and surgical interventions, further propelling market growth.

### Increasing Awareness of Fertility Issues

The growing awareness of fertility issues among the population is a crucial driver for the fertility drug-surgery market. Educational campaigns and media coverage have highlighted the challenges faced by couples trying to conceive, leading to a surge in consultations with fertility specialists. In South Korea, approximately 15% of couples experience infertility, prompting many to seek medical assistance. This heightened awareness has resulted in increased demand for fertility drugs and surgical interventions, as individuals become more proactive in addressing their reproductive health. The fertility drug-surgery market is likely to benefit from this trend, as more people recognize the importance of early intervention and the available treatment options.

### Advancements in Reproductive Technologies

Advancements in reproductive technologies are transforming the landscape of the fertility drug-surgery market. Innovations such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing have enhanced the success rates of fertility treatments. In South Korea, the success rate of IVF has improved to approximately 40%, encouraging more couples to pursue these options. These technological advancements not only increase the effectiveness of treatments but also expand the range of services offered by fertility clinics. As a result, the fertility drug-surgery market is likely to experience growth as patients seek out the latest and most effective reproductive technologies.

## Future Outlook

The [Fertility Drug Surgery Market](https://www.marketresearchfuture.com/reports/fertility-drug-surgery-market-7588) is projected to grow at a 6.79% CAGR from 2025 to 2035, driven by technological advancements, increasing infertility rates, and enhanced healthcare access.

**New opportunities:**

- Development of personalized fertility treatment plans leveraging AI technology.
- Expansion of telemedicine services for remote fertility consultations.
- Investment in fertility preservation technologies for cancer patients.

By 2035, the market is expected to achieve substantial growth, reflecting evolving consumer needs and technological innovations.

## Segment Insights

### By Underlying Cause: Female (Largest) vs. Male (Fastest-Growing)

In the South Korea fertility drug-surgery market, the distribution of market share between male and female segments reveals a substantial focus on female fertility treatments. The female segment dominates as the primary share holder, reflecting the higher demand for assisted reproductive technologies such as IVF and ovulation induction medications. Meanwhile, the male segment, while smaller in market share, exhibits a notable increase in its adoption of fertility solutions, driven by rising awareness of male infertility and advancements in treatment options.

Growth trends in this market segment are characterized by a significant increase in male fertility treatments as societal attitudes shift towards recognizing male infertility as a critical issue. Additionally, the increasing number of couples seeking fertility assistance has led to a rise in demand for male-related fertility drugs and surgical interventions. This trend points to a broader acceptance of male fertility issues, suggesting that the male segment may witness accelerated growth in the coming years as more men seek help and treatment, fostering a more balanced approach to fertility solutions.

Female (Dominant) vs. Male (Emerging)

The female segment in the South Korea fertility drug-surgery market is characterized by an established presence, driven by extensive offerings in reproductive technology and various fertility medications tailored to women's needs. As the dominant player, it benefits from a strong focus on comprehensive care, including hormonal treatments and surgical options like laparoscopy. On the other hand, the male segment, which is still considered emerging, is gaining momentum as awareness of male fertility issues rises. Innovative treatments such as sperm retrieval techniques and hormonal therapies have begun to carve out a niche, although they currently hold a smaller market share. This evolving scenario indicates that while the female sector remains predominant, the male segment is poised for rapid growth, attracting attention from both healthcare providers and patients.

### By Drug: Clomiphene Citrate (Largest) vs. Letrozole (Fastest-Growing)

In the South Korea fertility drug-surgery market, Clomiphene Citrate holds the largest market share among fertility drugs, attributed to its long-standing effectiveness and affordability. Its usage remains prevalent due to widespread awareness and acceptance among both healthcare providers and patients. Letrozole, while a newer entrant, is rapidly gaining traction due to its efficacy in triggering ovulation, particularly in patients who may not respond to Clomiphene, making it a considerable competitor in this segment.

The growth trends in this market are largely driven by increasing infertility rates coupled with rising awareness regarding fertility treatments. A shift towards more innovative therapies, such as Letrozole, highlights the market's adaptive nature. Additionally, supporting healthcare policies and advancements in reproductive health technologies provide favorable conditions for sustained growth in the sector.

Clomiphene Citrate: Dominant vs. Letrozole: Emerging

Clomiphene Citrate is recognized as the dominant drug within the South Korea fertility drug-surgery market due to its extensive clinical application and proven track record in treating ovulation disorders. It works by stimulating the release of hormones necessary for ovulation. In contrast, Letrozole, an emerging option, is becoming increasingly popular among specialists because of its efficacy and lower side effect profile. Letrozole functions as an aromatase inhibitor, promoting ovulation through a different mechanism. The growing preference for Letrozole among healthcare practitioners reflects a broader trend towards personalized treatment strategies aimed at maximizing patient outcomes.

### By Procedures: Hysteroscopy (Largest) vs. Laparoscopy (Fastest-Growing)

Hysteroscopy currently leads the market share among procedures in the South Korea fertility drug-surgery market, appealing to a wide range of patients due to its minimally invasive nature. Following closely are Laparoscopy and Robotic Laparoscopy, which have been gaining traction owing to advancements in surgical technology that enhance precision and reduce recovery times.

Growth trends indicate a promising future for Laparoscopy, which has emerged as the fastest-growing procedure attributed to increasing awareness and acceptance of minimally invasive techniques among patients and healthcare professionals. Additionally, factors such as rising infertility rates and a growing focus on reproductive health are further driving demand in this segment, positioning it for significant expansion in the coming years.

Hysteroscopy (Dominant) vs. Laparoscopy (Emerging)

Hysteroscopy is established as the dominant procedure in the South Korea fertility drug-surgery market, primarily due to its effectiveness in diagnosing and treating conditions within the uterus. It enables doctors to perform various interventions with a high level of accuracy and minimal discomfort to patients. Conversely, Laparoscopy, which includes robotic-assisted options, is rapidly emerging as a favored choice for its ability to provide similar benefits while offering enhanced surgical visibility and versatility. As patient preferences shift towards quicker recovery times and less invasive options, Laparoscopy is well-positioned to capture a larger market share, supported by ongoing technological improvements and a growing emphasis on personalized patient care.

### By End-User: Fertility Clinics (Largest) vs. Hospitals (Fastest-Growing)

In the South Korea fertility drug-surgery market, the distribution of market share among end-user segments reveals that fertility clinics hold the largest share, significantly contributing to overall market dynamics. Hospitals, while currently smaller in comparison, are experiencing rapid growth, indicating a shift in patient preferences towards hospital-based fertility treatments. Clinical research institutes and other sectors play supportive roles, but they represent a smaller fraction of the market landscape.

Growth trends in this segment are driven by several factors, including increasing awareness of fertility issues, advancements in reproductive technologies, and a rise in government support for fertility treatments. The growing number of individuals seeking fertility solutions as societal norms evolve is also propelling hospitals into a competitive position, with clinics needing to innovate continuously to retain their leading status.

Fertility Clinics (Dominant) vs. Hospitals (Emerging)

Fertility clinics are the dominant players in the South Korea fertility drug-surgery market, offering specialized services that cater to couples seeking assistance with infertility. These clinics are often equipped with the latest reproductive technologies and provide tailored treatment plans, which enhances patient satisfaction and outcomes. In contrast, hospitals are emerging as significant competitors due to their integrated healthcare services, which appeal to patients who prefer a more comprehensive approach involving multiple medical disciplines. Hospitals are expanding their fertility programs, driven by increasing investments in reproductive health services, thus providing more accessible options for patients. This dynamic is leading to a robust competition between fertility clinics and hospitals as they each strive to meet the evolving needs of clients.

## Competitive Benchmarking

The fertility drug-surgery market in South Korea is characterized by a dynamic competitive landscape, driven by increasing demand for assisted reproductive technologies and a growing awareness of [fertility issues](https://www.marketresearchfuture.com/reports/fertility-services-market-6281). Key players such as Merck KGaA (DE), Ferring Pharmaceuticals (CH), and AbbVie Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Merck KGaA (DE) focuses on expanding its product portfolio through research and development, while Ferring Pharmaceuticals (CH) emphasizes regional expansion and collaborations with local healthcare providers. AbbVie Inc. (US) is actively pursuing mergers and acquisitions to bolster its capabilities in reproductive health, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven.
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in technology and treatment options, thereby influencing overall market dynamics.
In October 2025, Merck KGaA (DE) announced a strategic partnership with a leading South Korean biotech firm to co-develop a novel fertility treatment. This collaboration is expected to enhance Merck's R&D capabilities and accelerate the introduction of innovative therapies tailored to the local market. Such partnerships are crucial in a landscape where localized solutions are increasingly valued by healthcare providers and patients alike.
In September 2025, Ferring Pharmaceuticals (CH) launched a new fertility drug specifically designed for the South Korean market, which aims to address unique patient needs. This product introduction not only reflects Ferring's commitment to innovation but also highlights its strategy of tailoring offerings to meet regional demands, thereby strengthening its competitive position.
In August 2025, AbbVie Inc. (US) completed the acquisition of a smaller fertility-focused company, enhancing its product pipeline and market reach. This acquisition is indicative of AbbVie's strategy to consolidate its position in the fertility sector, allowing it to offer a more comprehensive range of solutions to healthcare providers and patients.
As of November 2025, current trends in the fertility drug-surgery market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and reliable supply chains, positioning companies to better meet the complex needs of patients and healthcare providers.

## Recent News & Developments

In recent months, the South Korea Fertility Drug Surgery Market has witnessed significant developments. Notable advancements in technology, coupled with increasing public awareness surrounding fertility issues, have intensified the demand for fertility treatments. Companies like Celltrion and Samsung Biologics have reported enhanced capacities to produce biologic drugs targeting fertility enhancement, reflecting a growing focus in this sector. Furthermore, the market is experiencing growth with the government facilitating access to fertility treatments, exemplified by policies aimed at subsidizing costs for assisted reproductive technologies.

In terms of mergers and acquisitions, in March 2023, Hanmi Pharmaceutical announced its acquisition of a local biotech firm specializing in fertility solutions, enhancing its portfolio in this growing market. Additionally, Genexine's partnerships with international firms translated to expanded R&D investments localized in South Korea, fostering innovation in fertility drugs. The South Korean Fertility Drug Surgery Market was valued significantly higher in 2022 compared to the previous year, driven by factors such as rising infertility rates and increasing societal acceptance of fertility treatments.

Given these dynamics, the market appears poised for healthy growth moving forward, particularly with ongoing advancements in drug formulations and surgical techniques aimed at improving patient outcomes.

## Report Scope

| MARKET SIZE 2024 | 50.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 53.93(USD Million) |
| MARKET SIZE 2035 | 104.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.79% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck KGaA (DE), Ferring Pharmaceuticals (CH), Bayer AG (DE), AbbVie Inc. (US), Eli Lilly and Company (US), SAGE Therapeutics (US), HRA Pharma (FR), Irvine Scientific (US) |
| Segments Covered | Underlying Cause, Drug, Procedures, End-User |
| Key Market Opportunities | Emerging technologies in reproductive health enhance treatment options in the fertility drug-surgery market. |
| Key Market Dynamics | Rising demand for advanced fertility treatments drives innovation and competition in the fertility drug-surgery market. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the market valuation of the South Korea fertility drug-surgery market in 2024?**
A: The market valuation was $50.5 Million in 2024.

**Q: What is the projected market valuation for the South Korea fertility drug-surgery market in 2035?**
A: The projected valuation for 2035 is $104.0 Million.

**Q: What is the expected CAGR for the South Korea fertility drug-surgery market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.79% during the forecast period 2025 - 2035.

**Q: Which companies are key players in the South Korea fertility drug-surgery market?**
A: Key players include Merck KGaA, Ferring Pharmaceuticals, Bayer AG, AbbVie Inc., Eli Lilly and Company, SAGE Therapeutics, HRA Pharma, and Irvine Scientific.

**Q: What are the main segments of the South Korea fertility drug-surgery market?**
A: The main segments include Underlying Cause, Drug, Procedures, and End-User.

**Q: What was the valuation of the Drug segment in the South Korea fertility drug-surgery market in 2024?**
A: The Drug segment had a valuation of $56.5 Million in 2024.

**Q: What is the projected growth for the Procedures segment in the South Korea fertility drug-surgery market?**
A: The Procedures segment is expected to grow from $47.5 Million in 2024 to a higher valuation by 2035.

**Q: How does the End-User segment perform in the South Korea fertility drug-surgery market?**
A: The End-User segment was valued at $50.5 Million in 2024, with growth anticipated through 2035.

**Q: What are the specific valuations for male and female fertility treatments in the Underlying Cause segment?**
A: In the Underlying Cause segment, male treatments were valued at $62.5 Million and female treatments at $92.0 Million in 2024.

**Q: What are the anticipated trends in the South Korea fertility drug-surgery market by 2035?**
A: By 2035, the market is likely to see increased investments and advancements in fertility treatments, driven by the projected growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-fertility-drug-surgery-market-54009*